Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FAK/PTK2 drug discovery, covering small molecule inhibitors, PROTACs, and combination therapies.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Target | PTK2 Full-Length / Kinase Domain Recombinant Protein; FAK Kinase Domain/Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View PTK2 Products |
| Gene Delivery | PTK2 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View PTK2 Products |
| Benchmark Ab | Anti-PTK2 Recombinant Monoclonal (Research Grade); Anti-FAK Biosimilar Control. Sequence Verified positive control for Western/IP/IHC. | View PTK2 Products |
| Validator | PTK2 siRNA Set for knockdown verification. | View PTK2 Products |
| Related Target A | SRC (Non-Receptor Tyrosine Kinase) – Direct binding partner and synergistic signaling node. | View SRC Products |
| Related Target B | PIK3CA (PI3K Catalytic Subunit) – Downstream pathway effector for combination resistance studies. | View PIK3CA Products |
| Related Target C | KRAS – Synergistic pathway for overcoming targeted therapy resistance. | View KRAS Products |
| Related Target D | EGFR – Combination therapy rationale for solid tumors. | View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog selectivity (PTK2 vs PTK2B/PYK2) | High-purity PTK2 and PTK2B kinase domain proteins (>95% purity) for orthogonal counter-screening. |
| Drug resistance mutant profiling | Mutant recombinant panel (gatekeeper and activation loop variants). Sequence Verified. |
| Intracellular target engagement | Lentivirus-based stable overexpression cell lines. Full-length ORF. |
| Lack of assay controls | Research-grade recombinant antibody and validated siRNA for specificity and knockdown controls. |
| PROTAC Degradation Assays | High-purity recombinant targets for ternary complex formation validation. |
Live FAK/PTK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FAK/PTK2 therapeutics is intensifying. Major players are shifting focus from first-generation ATP-competitive inhibitors to next-generation modalities including PROTACs and combination regimens. Key trends include targeting kinase-independent scaffold functions, overcoming drug-resistant mutational escape, and modulating the tumor microenvironment (TME) to reverse immune evasion. First-generation small molecule inhibitors (e.g., Verastem’s Defactinib, InventisBio’s IN10018) are advancing in solid tumors, while PROTAC degraders are emerging as a strategy to eliminate both kinase and scaffolding functions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Kinase Inhibitors | Verastem, Incyte, GSK, InventisBio | Ovarian Cancer, Pancreatic Cancer, NSCLC | Kinase Selectivity Panel (high-purity PTK2 & PTK2B kinase domains) |
| PROTAC / Degrader | Various Biotechs | Refractory Solid Tumors | Ternary Complex & Degradation Assay (full-length PTK2 + E3 ligase components) |
| Combination Therapy (with PD-1/L1, KRASi, EGFRi) | Merck, Pfizer, Bristol Myers Squibb | Advanced Solid Tumors, Pancreatic Cancer | Pathway Combo Assays (need SRC, PIK3CA, KRAS, EGFR recombinant proteins) |